SEC EDGARSep 14$AMLX

Bedrosian Camille L sold $325K of AMLX

Bedrosian Camille L (Chief Medical Officer) sold 10,028 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.40 ($32.21–$33.09, $0.32M total) across 2 trades on 2026-09-10.

Original reporting

SEC EDGAR · Bedrosian Camille L

Published Sep 14, 2026, 8:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 14, 2026, 8:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$AMLX

Neutral

high confidence

Mentioned

$AMLX

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$AMLXNeutralLow

Why it matters

The disclosed sale is routine and unlikely to move the stock.

Market read

Minor insider sell with limited trading relevance.

What to watch

Potential upcoming clinical data not disclosed.

Relevance 4/10Novelty 4/10Timing: filed Sep 14, 2026

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMLXNeutralHigh confidence

Context

Chief Medical Officer sold 10,028 shares for $324,868, reducing insider holdings.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is modest relative to float and no new information disclosed.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to AMLX shareholders.

Counterpoint

What could challenge this read

Insider sell could signal concerns, but size is too small to act on.

Key entities

Company
Amylyx Pharmaceuticals, Inc.
Biotech company developing therapies for neurodegenerative diseases.
Executive
Camille L. Bedrosian
Chief Medical Officer of Amylyx.

Read at source ← All news

$AMLXMedAI 8/10

Amylyx Pharmaceuticals Q3 Earnings Call Highlights

Amylyx Pharmaceuticals reported Q3 operating expenses rose 38% to $49.7M, with R&D up 43% to $28.4M. The company plans to submit an FDA application for avexitide by year-end, targeting 160,000 U.S. patients with PBH. Amylyx is also advancing its pipeline, including AMX0318 and AMX0114, with a 2027 IND filing targeted for the former.

finance.yahoo.comNov 5

$AMLXHighAI 8/10

Amylyx Pharmaceuticals 3Q 2026: EPS ($0.38) — 10-Q Summary

Amylyx Pharmaceuticals reported no product revenue in Q3 2026, with a net loss of $45.49M, up 32.3% YoY. Higher R&D costs were partially offset by increased interest income. Avexitide's Phase 3 trial met its primary endpoint, and the company plans an NDA submission by year-end 2026. AMX0114 and AMX0318 are in early stages of development.

tradingview.comNov 5

$AMLXMedAI 8/10

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results • Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track • Results

SEC EDGAR 8-KNov 5

$AMLXLowAI 8/10

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.

finance.yahoo.comOct 3

$AMLXHighAI 8/10

Amylyx Stock Tumbles As Rally Meets Dilution Jitters

Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.

tipranks.comSep 18

$AMLXHigh

Why Is AMLX Stock Popping 14% After Hours?

Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.

stocktwits.comSep 12